Zhejiang Hisun Pharmaceutical Co., Ltd. announced about obtaining a permit for the industrial production of the world's first drug from coronavirus COVID-2019. Currently, the product has received all necessary approvals from the State administration for supervision of food and drugs and can go on sale, said in a company announcement on the Shanghai stock exchange.
the company said that it will continue clinical trials of the drug after its appearance on the market in a new way.
according to the report received at this time, the resolution is aimed at new indications, and clinical trials have not been carried out. After completing a series of clinical trials, their results will be presented for review and approval.
the Company warned potential investors on possible risks that affect national policy, market conditions and other factors.
"There are many uncertainties in the progress and results of the audit, as well as in the future the competitive situation on the product market", - summarized in the Zhejiang Hisun Pharmaceutical.
the Main content of the approval on the registration of drug
the
- the
- the name of the drug: Fairever pills (also known as: Failover pill) the
- Dosage form: tablet the
- Specification: 0.2 g the
- Issues use: registration of medicines in the country the
- Registration category: Chemical Category 3 the
- Pharmaceutical manufacturer Zhejiang Hisun Pharmaceutical Co., Ltd.
the Outbreak of the novel coronavirus recorded in the administrative center of Hubei province Wuhan at the end of December 2019. The world health organization (who) has declared it an emergency situation on an international scale and has been described as an epidemic, with many lesions.
According to the latest data of the Chinese authorities, the number of confirmed cases of infection with coronavirus reached 68.5 thousand. Outside the country confirmed the 526 cases. Died 1669 people.
